POET Technologies reports AGM results, production ramp plans

POET reaffirmed its production ramp to start in H2 2026 and target capacity of up to 1M units/month by end-2027, but shares are still down 8.2% over the last week amid investor skepticism. Financially, POET raised $830M in equity over the past 12 months (with up to an additional $661M from warrants) and recently completed a $400M registered direct offering at $21.00/share, while Q1 revenue of $503K missed the $2.2M consensus. Separately, Night Market Research disclosed a short position alleging overstated partnerships and questioned the status of the Celestial AI relationship, reinforcing a cautious near-term setup.

Analysis

POET is trading more like a funded development option than a scaled semiconductor business, which means the next 2-4 quarters should be judged on execution milestones, not headline cash. The large balance sheet reduces near-term insolvency risk, but it also raises the bar: every quarter without credible conversion from engagements to repeatable orders turns excess liquidity into a dilution shield for the bearish thesis, not a moat. That dynamic is most negative for other pre-revenue AI-photonics names, while established optics vendors with real shipments and operating leverage should look relatively cleaner.

The near-term risk is that the stock remains vulnerable to disclosure-driven gaps lower: weak bookings, vague customer references, or another short report can overwhelm any thematic AI-optics enthusiasm because there is little fundamental income statement support today. Over 6-18 months, the real catalyst is whether the 2H26 ramp becomes verifiable through customer PO cadence, gross margin path, and capex discipline; if those remain aspirational, valuation should compress via time decay rather than a balance-sheet event. Conversely, a documented conversion of design wins into production orders would force shorts to cover quickly because financing risk is already muted.

Consensus seems to be underweighting how long it can take for "engagements" to become revenue in this part of the supply chain, and over-weighting the value of cash when commercialization timing is still uncertain. The more interesting second-order effect is that if POET keeps funding ahead of proof, it can crowd out attention and capital from smaller photonics stories, while making high-quality peers like COHR, LITE, and FN look more attractive on a relative basis.

Key Decisions for Investors

• Tactically short POET into strength over the next 1-3 months; use a tight stop on any credible disclosure of customer conversion or booked production orders, because the balance sheet makes a financing squeeze less likely and raises squeeze risk.
• Pair trade: long FN or COHR vs short POET for the next 1-2 quarters to express 'real shipments over aspirational commercialization' in AI optics; this is a relative-quality trade, not a sector macro call.
• If already short POET, avoid adding immediately after down days; add only on failed rallies or after any follow-up filing that suggests timing slip, since the stock can remain headline-driven and borrow/squeeze-sensitive.
• Set an alert for the next revenue report and for any explicit customer-PO conversion language; if bookings do not improve while opex and hiring continue to ramp, the bearish thesis strengthens materially into 2026.